Soligenix invited to submit barda contract proposal for development of thermostabilized subunit vaccines for sudan ebola and marburg viruses

Emerging infectious diseases where n o protective vaccines are currently available suvax™ targets sudan ebolavirus, origin of a current disease outbreak in uganda princeton, n.j. , oct. 27, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the company has been invited by the biomedical advanced research and development authority (barda) division of chemical, biological, radiological and nuclear (cbrn) medical countermeasures to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection.
SNGX Ratings Summary
SNGX Quant Ranking